A Phase II, Randomized, Placebo-Controlled, Observer-Blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2016
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza virus vaccine
- Indications Influenza A virus H5N1 subtype; Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Mar 2008 New trial record.